CERo Therapeutics Holdings, Inc.(CERO),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

CERO CERo Therapeutics Holdings, Inc.

Pre-Mkt 10-23 16:00:00 EDT Delay

{"stockData":{"symbol":"CERO","market":"US","secType":"STK","nameCN":"CERo Therapeutics Holdings, Inc.","latestPrice":0.0048,"timestamp":1792785600000,"preClose":0.0051,"halted":0,"volume":103058,"delay":15,"changeRate":-0.05882352941176486,"floatShares":41849300,"shares":71631000,"eps":-13.2334,"marketStatus":"Pre-Mkt","change":-0.0003,"latestTime":"10-23 16:00:00 EDT Delay","open":0.0058,"high":0.0058,"low":0.0041,"amount":452.7999959999999,"amplitude":0.333333,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"otc":true,"ttmEps":-13.2334,"tradingStatus":1,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1793021400000},"marketStatusCode":1,"adr":0,"listingDate":1761883200000,"exchange":"OTCQB","adjPreClose":0.0048,"volumeRatio":0.3113800027770155},"requestUrl":"/m/hq/s/CERO/wiki","defaultTab":"wiki","newsList":[{"id":"2678196364","title":"SRX Global Announces UC Davis as New Site for CERo’s Phase 1 CER-1236 Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2678196364","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2678196364?lang=en_us&edition=fundamental","pubTime":"2026-10-26 21:07","pubTimestamp":1793020056,"startTime":"0","endTime":"0","summary":"SRX Global Announces UC Davis as New Site for CERo’s Phase 1 CER-1236 TrialSRX Global announced UC Davis as a new site for CERo Therapeutics’ ongoing Phase 1 CERTAIN-T trial of CER-1236 in blood cance","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261026:nNDL2y1cgm:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BGHQF748.EUR","LU2210150020.SGD","BK4128","IE00B64PRP62.GBP","IE00BQXX3C00.GBP","BK4585","LU2095319765.USD","SRXH","IE00BN0W2V16.EUR","NDAQ","BK4212","IE00BKPKM429.USD","IE00B3QW5Z07.USD","LU2210149790.SGD","IE00BQXX3D17.EUR","IE00BN0W2W23.USD","IE00BQXX3F31.USD","BK4139","SG9999014005.SGD","IE00BN0W2T93.GBP","BCDF","BK4112","BK4588","SG9999014039.USD","SG9999014021.USD","LU0314104364.USD","CERO","SG9999014013.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2678196387","title":"CERo Therapeutics Adds Fred Hutch Site to Phase 1 CER-1236 Cancer Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2678196387","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2678196387?lang=en_us&edition=fundamental","pubTime":"2026-10-26 21:06","pubTimestamp":1793020000,"startTime":"0","endTime":"0","summary":"CERo Therapeutics Adds Fred Hutch Site to Phase 1 CER-1236 Cancer TrialCERo Therapeutics activated Seattle’s Fred Hutch Cancer Center for its Phase 1 CERTAIN-T blood cancer trial of CER-1236 on Oct. 2","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261026:nNDL6DQ1n8:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BN0W2W23.USD","SG9999014005.SGD","BK4139","IE00BQXX3D17.EUR","LU2210149790.SGD","IE00B64PRP62.GBP","IE00B3QW5Z07.USD","BCDF","LU2210150020.SGD","BK4585","IE00BQXX3C00.GBP","IE00BKPKM429.USD","SG9999014039.USD","SG9999014013.SGD","IE00BN0W2T93.GBP","LU0314104364.USD","LU2095319765.USD","BK4112","IE00BGHQF748.EUR","NDAQ","CERO","SG9999014021.USD","IE00BN0W2V16.EUR","BK4588","IE00BQXX3F31.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2678196813","title":"Srx Global Announces Activation of the University of California, Davis as a Clinical Trial Site for Cero Therapeutics’ Ongoing Phase 1 Certain-T Trial of Cer-1236 in Hematologic Malignancies","url":"https://stock-news.laohu8.com/highlight/detail?id=2678196813","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2678196813?lang=en_us&edition=fundamental","pubTime":"2026-10-26 21:05","pubTimestamp":1793019900,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261026:nTUA4S51HH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["CERO","BK4139","BK4212","BK4128","SRXH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673542017","title":"Srx Global - Acquisition Expected to Accelerate Development of Cer-1236 for Hematologic Malignancies","url":"https://stock-news.laohu8.com/highlight/detail?id=2673542017","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673542017?lang=en_us&edition=fundamental","pubTime":"2026-10-08 03:00","pubTimestamp":1791399600,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261007:nTUACHDTLQ:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4212","SRXH","BK4128","BK4139","CERO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673175050","title":"Srx Global - Cero 1236, Spv to Raise Capital Without Diluting Srx Global Shareholders","url":"https://stock-news.laohu8.com/highlight/detail?id=2673175050","media":"THOMSON REUTERS","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673175050?lang=en_us&edition=fundamental","pubTime":"2026-10-08 03:00","pubTimestamp":1791399600,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261007:nTUACHDTLQ:5","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["CERO","SRXH","BK4128","BK4212","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673017546","title":"Srx Global - Andrew Kucharchuk Expected to Serve as President of Cero Therapeutics","url":"https://stock-news.laohu8.com/highlight/detail?id=2673017546","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673017546?lang=en_us&edition=fundamental","pubTime":"2026-10-08 03:00","pubTimestamp":1791399600,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261007:nTUACHDTLQ:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4212","BK4139","BK4128","CERO","SRXH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673017544","title":"Srx Global and Cero 1236, a Wholly-Owned Spv, Enter into Definitive Agreement to Acquire Cero Therapeutics, an Innovative Cellular Immunotherapy Company Developing Cer 1236 for Hematologic Malignancies","url":"https://stock-news.laohu8.com/highlight/detail?id=2673017544","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673017544?lang=en_us&edition=fundamental","pubTime":"2026-10-08 03:00","pubTimestamp":1791399600,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261007:nTUACHDTLQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["SRXH","CERO","BK4212","BK4128","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673090039","title":"SRX Global to Acquire CERo Therapeutics Unit from CERo Therapeutics Holdings","url":"https://stock-news.laohu8.com/highlight/detail?id=2673090039","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673090039?lang=en_us&edition=fundamental","pubTime":"2026-10-07 20:06","pubTimestamp":1791374767,"startTime":"0","endTime":"0","summary":"SRX Global to acquire CERo Therapeutics unit from CERo Therapeutics HoldingsSRX Global entered a deal to buy all shares of CERo Therapeutics, a wholly owned operating unit of CERo Therapeutics Holding","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261007:nNDL1bBF3n:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4212","00512","BK4139","BK1191","CERO","SRXH","BK4128"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664841988","title":"SRX Global Buys Senior Secured Debt in CERo Therapeutics Holdings","url":"https://stock-news.laohu8.com/highlight/detail?id=2664841988","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664841988?lang=en_us&edition=fundamental","pubTime":"2026-09-03 04:48","pubTimestamp":1788382101,"startTime":"0","endTime":"0","summary":"SRX Global buys senior secured debt in CERo Therapeutics HoldingsSRX Global bought senior secured debt in CERo Therapeutics Holdings to fund development of its engineered T-cell therapy program.Procee","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260902:nNDL7ZD6Wn:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4212","CERO","BK4128","SRXH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663070565","title":"SRX Global Buys Senior Secured Debt in CERo Therapeutics Holdings","url":"https://stock-news.laohu8.com/highlight/detail?id=2663070565","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2663070565?lang=en_us&edition=fundamental","pubTime":"2026-08-31 19:30","pubTimestamp":1788175858,"startTime":"0","endTime":"0","summary":"SRX Global buys senior secured debt in CERo Therapeutics HoldingsSRX Global bought senior secured debt in CERo Therapeutics Holdings to provide additional capital for CERo’s clinical programs.CERo has","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260831:nNDLb7ZvSz:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4128","SG9999014021.USD","LU2210149790.SGD","SG9999014005.SGD","BK4139","IE00BKPKM429.USD","IE00BN0W2W23.USD","BCDF","BK4585","LU2095319765.USD","BK4112","NDAQ","LU0314104364.USD","IE00BQXX3F31.USD","SG9999014013.SGD","BK4588","SG9999014039.USD","IE00BGHQF748.EUR","IE00B64PRP62.GBP","LU2210150020.SGD","IE00BQXX3C00.GBP","IE00BN0W2T93.GBP","IE00B3QW5Z07.USD","SRXH","BK4212","CERO","IE00BN0W2V16.EUR","IE00BQXX3D17.EUR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663907032","title":"Srx Global Acquires Senior Secured Debt in Cero Therapeutics Holdings, Inc., an Innovative Cellular Immunotherapy Company with Cancer Fighting Molecule for the Treatment of Hematologic Cancers","url":"https://stock-news.laohu8.com/highlight/detail?id=2663907032","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2663907032?lang=en_us&edition=fundamental","pubTime":"2026-08-31 19:30","pubTimestamp":1788175800,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260831:nTUA7HMYNN:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4128","BK4139","CERO","SRXH","BK4212"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663070340","title":"Srx Global - Investment Expected to Accelerate Cero Clinical Program Advancement","url":"https://stock-news.laohu8.com/highlight/detail?id=2663070340","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2663070340?lang=en_us&edition=fundamental","pubTime":"2026-08-31 19:30","pubTimestamp":1788175800,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260831:nTUA7HMYNN:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["SRXH","BK4212","BK4128","BK4139","CERO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663151580","title":"SRX Global Sells 3,579 Series C Preferred Shares in Private Placement Valued at $2.86 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2663151580","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2663151580?lang=en_us&edition=fundamental","pubTime":"2026-08-29 05:03","pubTimestamp":1787951029,"startTime":"0","endTime":"0","summary":"SRX Global sells 3,579 Series C preferred shares in private placement valued at $2.86 millionSRX Global entered a private placement on Aug. 27, 2026, issuing 3,579 shares of Series C convertible prefe","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260828:nNDL6bXHbx:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4212","BK4139","BK4128","SRXH","CERO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659129895","title":"Cero Therapeutics Q2 FY26 Net Loss Narrows 81% to $1.03 Million; R&D Expenses Fall 37% to $1.74 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2659129895","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659129895?lang=en_us&edition=fundamental","pubTime":"2026-08-15 04:12","pubTimestamp":1786738341,"startTime":"0","endTime":"0","summary":"Cero Therapeutics Q2 FY26 net loss narrows 81% to $1.03 million; R&D expenses fall 37% to $1.74 millionCero Therapeutics posted a Q2 net loss of USD 1.03 million, narrowing 81% from the prior-year qua","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260814:nNDL2YJV02:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","CERO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649988359","title":"Ovid Therapeutics Names Kevin Norrett Chief Business Officer","url":"https://stock-news.laohu8.com/highlight/detail?id=2649988359","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2649988359?lang=en_us&edition=fundamental","pubTime":"2026-07-08 19:01","pubTimestamp":1783508472,"startTime":"0","endTime":"0","summary":"Ovid Therapeutics names Kevin Norrett chief business officerOvid Therapeutics named Kevin Norrett chief business officer to lead business development, corporate development, strategic partnerships.Nor","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260708:nNDLb5KgZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CDXS","LU1645745479.HKD","IE00B3T34201.USD","LU1670756490.USD","NBIX","LU0306807586.USD","LU0225771236.USD","CERO","LU0109394709.USD","GSK.UK","IE00B3QW5Z07.USD","OVID","BK4112","LU0321505868.SGD","LU0971552673.USD","LU0203347892.USD","IE00BN0W2W23.USD","LU0545562505.USD","LU0985481810.HKD","SG9999013999.USD","BCDF","LU2065171402.SGD","SG9999001176.USD","LU2468319806.SGD","SG9999014021.USD","SG9999001176.SGD","IE0034235071.USD","IE00B64PRP62.GBP","LU0971552830.HKD","LU2210149790.SGD","IE00BWDBJ516.SGD","BK4121","SG9999014005.SGD","SG9999014013.SGD","LU2065171311.SGD","LU0575583348.USD","NDAQ","LU2089984988.USD","LU1046248800.SGD","LU0154245756.USD","IE00BGHQF748.EUR","LU0058720904.USD","BK4139","LU1302929846.USD","LU1400636491.USD","LU0321505439.SGD","LU0306806265.USD","LU0161305163.EUR","LU2095319765.USD","LU1202635105.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2646360818","title":"Cero Therapeutics Amends SRX Health Promissory Note, Lifts Borrowing Capacity to $1.41 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2646360818","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2646360818?lang=en_us&edition=fundamental","pubTime":"2026-06-27 04:06","pubTimestamp":1782504398,"startTime":"0","endTime":"0","summary":"Cero Therapeutics amends SRX Health promissory note, lifts borrowing capacity to $1.41 millionCero Therapeutics entered an amended and restated promissory note with SRX Health Solutions on June 23, 20","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260626:nNDL6tbSzF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CERO","BK4139","BK4128","BK4212","SRXH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643203116","title":"CERo Therapeutics says AML patient in CER-1236 Phase 1 trial proceeds to allogeneic stem cell transplant","url":"https://stock-news.laohu8.com/highlight/detail?id=2643203116","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2643203116?lang=en_us&edition=fundamental","pubTime":"2026-06-15 20:15","pubTimestamp":1781525741,"startTime":"0","endTime":"0","summary":"Cero Therapeutics reported a Phase 1 CERTAIN-T update for its CER-1236 cell therapy in blood cancers; results were previously presented in February.Investigators described clinical improvement in some treated patients, including one AML patient who proceeded to an allogeneic stem cell transplant.Safety to date remained consistent with earlier disclosures, with no severe treatment-related events reported during the key early monitoring window.Six patients have been treated so far; the study has moved into its third planned cohort as dose escalation continues.The next cohort targets a higher planned dose and broadens screening to additional myeloid diseases, including MDS and myelofibrosis.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260615:nNDLf6qs9:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BN0W2V16.EUR","CERO","IE00BN0W2W23.USD","SG9999014039.USD","BK4585","BK4112","LU2210149790.SGD","IE00BKPKM429.USD","IE00B3QW5Z07.USD","BK4139","SG9999014013.SGD","LU2095319765.USD","IE00BN0W2T93.GBP","LU0314104364.USD","IE00B64PRP62.GBP","BK4588","NDAQ","SG9999014005.SGD","IE00BGHQF748.EUR","SG9999014021.USD","LU2210150020.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643203943","title":"Cero Therapeutics Announces Clinical Update From Certain-T Phase 1 Cer-1236 Trial, Including Patient Undergoing Allogeneic Stem Cell Transplant Following Treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=2643203943","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2643203943?lang=en_us&edition=fundamental","pubTime":"2026-06-15 20:15","pubTimestamp":1781525700,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260615:nTUA8BFCFQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["CERO","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2639672223","title":"Cero Therapeutics issues USD 750,000 convertible note to SRX Health Solutions","url":"https://stock-news.laohu8.com/highlight/detail?id=2639672223","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2639672223?lang=en_us&edition=fundamental","pubTime":"2026-05-30 04:07","pubTimestamp":1780085266,"startTime":"0","endTime":"0","summary":"Cero Therapeutics entered a USD 750,000 convertible promissory note financing with SRX Health Solutions on May 28, 2026.Note carries USD 937,500 principal face value, 10% annual interest, maturity on May 28, 2027.Lender can convert principal and interest at the lower of USD 0.05 or 80% of a 20-day lookback pricing formula.Conversion is subject to a 4.99% beneficial ownership cap; company plans to file a resale registration statement for conversion shares.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cero Therapeutics Holdings Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on May 29, ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260529:nNDL2fDVDy:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","CERO","BK4212","SRXH","BK4128"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636009923","title":"60 Degrees Pharma appoints Eric Francois to board","url":"https://stock-news.laohu8.com/highlight/detail?id=2636009923","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2636009923?lang=en_us&edition=fundamental","pubTime":"2026-05-19 04:33","pubTimestamp":1779136427,"startTime":"0","endTime":"0","summary":"60 Degrees Pharmaceuticals appointed Eric Francois to its board on May 13, 2026, effective immediately.Francois is an independent director at CERo Therapeutics Holdings.He previously served as a managing director in healthcare investment banking at Raymond James and Credit Suisse.He was also CFO of SCYNEXIS, overseeing finance and corporate development through its FDA approval and commercial launch.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. 60 Degrees Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on May 18, 2026, and is solely responsible for the information conta","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260518:nNDL1zNXxB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BGHQF748.EUR","SXTP","RJF","IE00B64PRP62.GBP","BK4139","LU1804176565.USD","CERO","BK4007","BK4585","BK4588","SCYX","LU0971096721.USD","LU2265009873.SGD","BK4127","LU1363072403.SGD","IE00B3QW5Z07.USD"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.cero.bio","description":"CERo Therapeutics Holdings, Inc., an immunotherapy company, focuses on advancing the development of engineered T cell therapeutics for the treatment of cancer. Its lead development candidate is CER-1236, an autologous T cell therapy candidate for the treatment of hematologic malignancies. The company was incorporated in 2021 and is based in South San Francisco, California.","exchange":"OTCQB","name":"CERo Therapeutics Holdings, Inc.","nameEN":"CERo Therapeutics Holdings, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.52.0","shortVersion":"4.52.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"CERo Therapeutics Holdings, Inc.(CERO),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest CERo Therapeutics Holdings, Inc.(CERO) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"CERo Therapeutics Holdings, Inc.,CERO,CERo Therapeutics Holdings, Inc.股票,CERo Therapeutics Holdings, Inc.股票老虎,CERo Therapeutics Holdings, Inc.股票老虎国际,CERo Therapeutics Holdings, Inc.行情,CERo Therapeutics Holdings, Inc.股票行情,CERo Therapeutics Holdings, Inc.股价,CERo Therapeutics Holdings, Inc.股市,CERo Therapeutics Holdings, Inc.股票价格,CERo Therapeutics Holdings, Inc.股票交易,CERo Therapeutics Holdings, Inc.股票购买,CERo Therapeutics Holdings, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"CERo Therapeutics Holdings, Inc.(CERO),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest CERo Therapeutics Holdings, Inc.(CERO) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction